CCI4EU - Molecular diagnostics and precision medicine

04 December 2024

Chairs: Anna Sapino, IT - Olli Carpen, FI - Rui Henrique, PT

Introduction

CCI4EU (Comprehensive Cancer Infrastructures for the European Union) is a European project aiming to help Member States and Associated Countries improve or develop their existing or future Comprehensive Cancer Infrastructures (CCIs), by helping develop their research & innovation-related capacities.

This course is one of 10 online training courses organised within the project to help countries develop an effective comprehensive infrastructure and widen the reach of this grant. The topic of this online course is Molecular diagnostics and precision medicine.

Target audience
Pathologists, researchers, management, coordinators, patient advocates.

Course delivery

This online course was held live on 4th December via this webpage. The entire course was recorded and is now available as on-demand material.

To access the on-demand materials (after the live streaming), participants must register to the course, login to the e-ESO platform and click on the play buttons inside the course programme.

Official language

The course was held in English. Translations are not provided, but English subtitles can be activated and transcriptions can be automatically translated using free online tools.

Registration

Registration to the course is free but mandatory. Registration will be confirmed by e-mail.

Certificate of attendance

Participants (both live and on-demand) will be issued a certificate of attendance once they have completed a minimum attendance of 75% of the entire course. An online evaluation questionnaire must be completed in order to receive the certificate that will be issued by email. The evaluation questionnaire will appear in the right-hand column of the course page when participants have completed the course.

Organising secretariat

Sarah Goldman: sgoldman@eso.net

Francesca Marangoni: fmarangoni@eso.net

Sonia Bulgarelli: sbulgarelli@eso.net

LIVE STREAMING

04/12/2024

Welcome and introduction

04/12/2024

Chairs:

Olli Carpén, FI - Rui Henrique, PT - Anna Sapino, IT

Opportunistic genetic screening for breast cancer predisposition

04/12/2024

Expert:

Minja Pehrsson, FI

Discussion

Expert:	Minja Pehrsson, FI
Chair:	Olli Carpén, FI

Molecular Diagnostics and precision medicine

04/12/2024

Molecular Diagnostics: where we are today: aim, techniques

Expert:

Umberto Malapelle, IT

Molecular Diagnostics: where we are going in the future

Expert:

Albrecht Stenzinger, DE

Practical Implementations: what is needed, coordination, resources, delivery, budgets, challenges

Example 1 - Good example of using molecular diagnosis approaches

Expert:

Caterina Marchiò, IT

Example 2 - Good example of using molecular diagnosis approaches

Expert:

Marius Ilié, FR

Discussion

Experts:

Marius Ilié, FR - Umberto Malapelle, IT - Caterina Marchiò, IT - Albrecht Stenzinger, DE

Molecular Tumour Boards

04/12/2024

The Importance of Molecular Tumour Boards

Expert:

Laura Mezquita, ES

How to create/implement/co-ordinate Molecular Tumour Boards

Expert:

Rodrigo Dienstmann, ES

Molecular Tumour Boards: Protocols and Regulations

Example 1 - example of how MTB organized in Italy

Expert:

Gennaro Ciliberto, IT

Example 2 - example of how MTB organized in Norway

Expert:

Sigmund Brabrand, NO

Discussion

Experts:

Sigmund Brabrand, NO - Gennaro Ciliberto, IT - Rodrigo Dienstmann, ES - Laura Mezquita, ES

BREAK

04/12/2024

Financial issues in precision medicine

04/12/2024

Case 1 - Example reimbursement model

Expert:

Bengt Jönsson, SE

Case 2 - Example reimbursement model

Expert:

Nicola Normanno, IT

Discussion on sustainability: pros, cons and challenges

Experts:

Bengt Jönsson, SE - Nicola Normanno, IT

Patient advocate

04/12/2024

The importance of patient advocates to implement molecular diagnostics and precision medicine

Expert:

Bettina Ryll, SE

Discussion

Expert:	Bettina Ryll, SE
Chair:	Rui Henrique, PT

Clinical Trials in precision medicine

04/12/2024

Ongoing clincial trials in place

Expert:

Åslaug Helland, NO

Future of clinical trials

Expert:

Vanesa Gregorc, IT

Discussion

Experts:

Vanesa Gregorc, IT - Åslaug Helland, NO

Closing remarks

04/12/2024

Chairs:

Olli Carpén, FI - Rui Henrique, PT - Anna Sapino, IT

Sigmund Brabrand

Oslo University Hospital, Oslo, Norway

Olli Carpén

Professor and Chair of Pathology, University of Helsinki, Helsinki, Finland

Gennaro Ciliberto

National Cancer Institute Regina Elena, Rome, Italy

Rodrigo Dienstmann

Vall d’Hebron Institute of Oncology, Barcelona, Spain

Vanesa Gregorc

Istituto di Candiolo IRCC, Torino, Italy

Åslaug Helland

Research Director, Oslo Comprehensive Cancer Center, Oslo University Hospital, Oslo, Norway

Rui Henrique

Director of the Pathological Anatomy Service, Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E., Porto, Portugal

Marius Ilié

Professor of Pathology, Pasteur Hospital CHU; Institute of Research on Cancer and Ageing of Nice, Nice, France

Bengt Jönsson

Professor Emeritus, Department of Economics, Stockholm School of Economics, Stockholm, Sweden

Umberto Malapelle

Pathologist, University of Naples Federico II, Naples, Italy

Caterina Marchiò

Candiolo Institute (IRCCS), Candiolo, Italy

Laura Mezquita

Adjunct Professor of Medicine, University of Barcelona, Barcelona, Spain

Nicola Normanno

Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy

Minja Pehrsson

Clinical laboratory geneticist, HUS Helsinki University Hospital, Helsinki, Finland

Bettina Ryll

Melanoma Patient Network Europe, Uppsala, Sweden

Anna Sapino

Pathologist, IRCCS Istituto di Candiolo, Candiolo, Italy

Albrecht Stenzinger

Head of Molecular Pathology, Heidelberg University Hospital, Heidelberg, Germany

04 December 2024

This course is part of

Funded by